Pipettes in a lab

Natalizumab

Natalizumab (Tysabri) is already licensed to treat highly active relapsing MS. It's been trialled for people with progressive MS.

Current phase of trial: Phase 2/3.

Type of MS: Primary and secondary progressive MS

Find out more about natalizumab

  • How does natalizumab work?
  • How is natalizumab taken?
  • Latest research
  • What are the side effects of natalizumab?
  • How does natalizumab compare with other therapies?
  • When will natalizumab be available?